SCHEMBL4283450

SCHEMBL4283450

CN1CCN(C(=O)c2cc(-c3cccs3)on2)CC1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 11/20 0.79
NPC1 O15118 9/20 0.79
SMN1; SMN2 Q16637 8/20 0.79
ALDH1A1 P00352 7/20 0.79
HPGD P15428 6/20 0.79
TP53 P04637 2/20 0.79
LMNA P02545 6/20 0.74
MAPT P10636 2/20 0.74
ALOX15 P16050 1/20 0.74
MAPK1 P28482 1/20 0.74
TSHR P16473 5/20 0.69
PAX8 Q06710 1/20 0.69
NPSR1 Q6W5P4 1/20 0.69
CYP1A2 P05177 1/20 0.69
CYP3A4 P08684 1/20 0.69
CYP2C9 P11712 1/20 0.69
CYP2C19 P33261 1/20 0.69
HTT P42858 2/20 0.60
KDM4E B2RXH2 2/20 0.55
MEN1 O00255 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4288302 0.89 NPC1 (0.97) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL2526391 0.88 NPC1 (1.00) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL4286617 0.88 NPC1 (1.00) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL4278767 0.87 RAB9A (1.00) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL4286780 0.87 RAB9A (0.79) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL4280051 0.86 SMN1; SMN2 (0.73) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL9911613 0.86 RAB9A (0.77) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL4280282 0.86 RAB9A (0.69) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL1477294 0.84 LMNA (0.73) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL1474031 0.81 LMNA (0.72) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404304-B1 Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same SIERRA SCIENCES, LLC (US) 2025-09-02 US disclosed
US-20250179122-A1 Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same SIERRA SCIENCES, LLC 2025-06-05 US disclosed
US-20140364467-A1 CHEMICAL INDUCERS OF NEUROGENESIS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-12-11 US disclosed
US-20140364467-A1 CHEMICAL INDUCERS OF NEUROGENESIS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-12-11 US disclosed
US-8778940-B2 Chemical inducers of neurogenesis THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-07-15 US disclosed
US-8778940-B2 Chemical inducers of neurogenesis THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-07-15 US disclosed
US-20130143885-A1 CHEMICAL INDUCERS OF NEUROGENESIS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-06-06 US disclosed
US-20130143885-A1 CHEMICAL INDUCERS OF NEUROGENESIS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-06-06 US disclosed
US-8193225-B2 Isoxazole amides, derivatives and methods of chemical induction of neurogenesis THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-06-05 US disclosed
US-8193225-B2 Isoxazole amides, derivatives and methods of chemical induction of neurogenesis THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-06-05 US disclosed
US-20090143451-A1 COMPOUNDS THAT INCREASE TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION AND METHODS FOR USING THE SAME SIERRA SCIENCES INC. 2009-06-04 US disclosed
US-20090036451-A1 Chemical inducers of neurogenesis THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2009-02-05 US disclosed
US-20090036451-A1 Chemical inducers of neurogenesis THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179122-A1 Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same TERT, RNGTT, TERF2 RAB9A 4044/4885NPC1 2894/4885SMN1; SMN2 487/4885
US-20140364467-A1 CHEMICAL INDUCERS OF NEUROGENESIS DCX, NES, GAP43 RAB9A 2878/4885NPC1 1941/4885SMN1; SMN2 929/4885
US-12404304-B1 Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same TERT, TELO2, POT1 RAB9A 4662/4885NPC1 4442/4885SMN1; SMN2 1264/4885
US-20090143451-A1 COMPOUNDS THAT INCREASE TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION AND METHODS FOR USING THE SAME TERT, TERF2, RNMT RAB9A 3970/4885NPC1 2996/4885SMN1; SMN2 908/4885
US-20090036451-A1 Chemical inducers of neurogenesis DCX, NES, GAP43 RAB9A 2878/4885NPC1 1941/4885SMN1; SMN2 929/4885
US-20130143885-A1 CHEMICAL INDUCERS OF NEUROGENESIS DCX, NES, GAP43 RAB9A 2878/4885NPC1 1941/4885SMN1; SMN2 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.